MK2140-011 A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL)



Mary Beth Wilwerding, RN Admin@NEcancertrials.com



Available at Nebraska Hematology and Oncology, Lincoln, NE location

Interested in More Information?

Please fill out the form below. Someone will get back to you as soon as possible.

"*" indicates required fields

Name*

Email*

Phone*

Message*